UPDATE: Dougherty & Company Upgrades Hologic to Buy

Dougherty & Company upgrades Hologic

from Neutral to Buy in a research report out today and has a $26 price target on the company's shares. In the research report, Dougherty & Company writes, "BOTTOM-LINE: Hologic's academic collaborator introduced incremental Tomosynthesis data this past weekend at the ECR Meeting in Vienna, demonstrating that C-View software + TOMO can identify more cancers (77% of cancers identified in cohort) versus FFDM alone (57% of cancers identified in cohort). We suspect Hologic could submit CView to FDA by YE12." Shares of Hologic are currently trading at $20.39, down 0.24% from Friday's market close.